Bioinformatics, 35(22), 2019, 4664–4670
doi: 10.1093/bioinformatics/btz298
Advance Access Publication Date: 30 April 2019
Original Paper

OXFORD

Structural bioinformatics

Dynamical important residue network (DIRN): network inference via conformational change

Quan Li[1], Ray Luo[2,3,4,5,6,*] and Hai-Feng Chen[1,*]

[1]State Key Laboratory of Microbial Metabolism, Department of Bioinformatics and Biostatistics, National Experimental Teaching Center for Life Sciences and Biotechnology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China, [2]Department of Molecular Biology and Biochemistry, [3]Department of Chemical and Biomolecular Engineering, [4]Department of Materials Science and Engineering, [5]Department of Biomedical Engineering, University of California, Irvine, CA 92697, USA and [6]Department of Chemistry, Southern University of Science and Technology, Shenzhen 518055, Guangdong, China

*To whom correspondence should be addressed.
Associate Editor: Alfonso Valencia

Received on December 13, 2018; revised on March 19, 2019; editorial decision on April 16, 2019; accepted on April 18, 2019

Abstract

Motivation: Protein residue interaction network has emerged as a useful strategy to understand the complex relationship between protein structures and functions and how functions are regulated. In a residue interaction network, every residue is used to define a network node, adding noises in network post-analysis and increasing computational burden. In addition, dynamical information is often necessary in deciphering biological functions.

Results: We developed a robust and efficient protein residue interaction network method, termed dynamical important residue network, by combining both structural and dynamical information. A major departure from previous approaches is our attempt to identify important residues most important for functional regulation before a network is constructed, leading to a much simpler network with the important residues as its nodes. The important residues are identified by monitoring structural data from ensemble molecular dynamics simulations of proteins in different functional states. Our tests show that the new method performs well with overall higher sensitivity than existing approaches in identifying important residues and interactions in tested proteins, so it can be used in studies of protein functions to provide useful hypotheses in identifying key residues and interactions.

Contact: ray.luo@uci.edu or haifengchen@sjtu.edu.cn

Supplementary information: Supplementary data are available at *Bioinformatics* online.

1 Introduction

P te tu du ea d b ca ac vt -a e d te ed b- t c te- e d e te ac (D Pa a *et al.*, 2013). Re d e te- ac d a f c tat a d d te ded t tac et e d e at - u e a - te- e d e te- ac a d ave bee u edt a te et e t a- a ca (A bet *et al.*, 2000; A e v *et al.*, 2008). Of e t e, t ee d ca det f - tat e d e t a a e- e b e uc a te f d , a te g at a- a de (- ca- ta - (De S *et al.*, 2007; D - a *et al.*, 2002; Su da a a a *et al.*, 2010; Si e *et al.*, 2003). T e- ca a bu edt de t f e- e d e a a te g at a - a a e f be (C e , 2008; C e a d Lu , 2007; G *et al.*, 2017; J a *et al.*, 2016; L a d C e , 2018; Lu *et al.*, 2017; Ra a *et al.*, 2016; Wa *et al.*, 2016; Ya *et al.*, 2016; Ye *et al.*, 2017; Z a *et al.*, 2017).

I a a - te tu du e t I te ac N (IN) (A a *et al.*, 2004) d , eve - e d e u edt def ea c- de. If a - a tu du e a eu ed, c tat f te ac- t bt ee de eu e ve a a fat bt ee

2 Materials and methods

2.1 Overview of the method

2.2 MD simulations



Fig. 1. Flow chart of the DIRN approach

T e d t a e d t u d u e f a d t a c d t f e a c t e c a b e f u d t e S e e t a - M t d. T u d t e d f f e e t c f a d - a c d f f e e t c d t , f v e d g e d e t t a e d e f 160 e a c e e a t e d f e v e - t e t e d S e e t a - Tab e S1. E t e a t d t a a e t e S e e t a - M t d.

2.3 MD simulation post-analysis

MD t - a a - u e d e d t a t , t u d u a d t a c e a d t e a t a a - e. T e f t a t a t d e f - t a t e - d e t t a b e c a e b - a a - t e t u d u a d t a. T a a d e d t - u e - a e v e d f MDT a (McG b b *et al.*, 2015). A t u d u a d t a t d c e d e a e, D, T-a, C 1 C 4, O e a, J c, J b a d J a e e c t e d f e a c e d e f a - b - f a e e a c t a e d - Dat c e c t a c d c t e d a f e e t e v e u b a t. T e d t a c t c a b e c a f e d t t e e u b c a e b - d t a t - e. F a e, D, T-a, C 1 C 4 a d O e a a e a d a t - e; a d J c, J b a d J a a e f a t - e. I a d d t, t e e d t a c a - t i t e b e c a f e d t t u c t e t e - d e d e - d e. F a e, T-a d e d t e e d e.

T e e c d a t a t a a - e t e a c a t a t e d e t e t d e f i t e d v f c e f c f a c a e. P t e c f a c a e c a b e a t b t e d t e - e d e t e a c u c a - d e - b d, - d b c a d e e c - t a c t e a c. T e f e, e d e t f e d a b e t e a c b - a a - a (L a d C e, 2018; Wa *et al.*, 2014). H - d b c a d e e c t a c t e a c e e d e t f e d f t e - e d e d t a c e <0.6 He e t e d t a c e c a t e d t e a c e v e t a a c d e d. H - d e - b d t e - a c e e d e t f e d f d a c c e p t d t a c e <0.35 a d t e b d a e a e t a 2.09 a d a. A t e e t - e f t e a c - t e e e a c e d f a a t a e d e a d a MD f a e t a t a b e t e a c f e a c t - e c a b e d e f e d a f. F - d b c a d e e c t a c t e a c, t e - a e t a b e f t e a u a t a e e t a 75% (G a c a-G a c a *et al.*, 2003). F - d e b d, t e - a e t a b e f t e a u a t a e e t a 30% (C e, 2008).

2.4 Residue interaction network and shortest-path analysis

Re d a - e v e t e a c t d - e e c t u c t e d f u b - e d d t d e t f e d a t a t e d e / a d a c t - d e (C e - 2008; Lu a d Hu, 2011) (e d a t a f a a e S e e t a - Mat e a).

3 Results

I t e f, e f t - e e t t e d a t a e d d e v e - e t a e f f t f u d e d b - f u S e. (3) a d (4) f t e a t T f e d b - v a d a t f t e e d d e u c e a - a e PKM2 a d t GPCR M2 a d OR. F a - t e e d d a c a e d t t t e d.

3.1 Algorithm development

G v e t e c e c t e d t u d u a d a t a f MD a t, t e f t t e t e a t t c d d c a a e t f e a c e d e a d e a c t u d u a d a t a f e a c - a f t a e c t e t a - e f a t c d t. T e u t u t t e v e a a t e ( ) c c a - a c t e (t e d e e e f v e a b t e e t e t a - e (t u d u a d a t a) f t e a f t a e c t e. G v e t e v e a a t e f a - a f t a e c t e, t e - e t t g t d e t f i - t a t e d e b - u d t a t e ($\delta = 1 -$) f a - a f t a e c t e. S e c f c a - , f t e d t a t e f a t u d u a d a t a f a e d e a - a f t a e c t e - e c e e d a v e t e d t a f e - u e c - , t e e d e a d t v a - b - a t a b e a - d t a d e c d e d a a t a t a t e d e f t u d u a f c a c e.

Pair alignment. A f e MD a t, e a c d a t a t - e f e a c e d e f e a c t a e c t - a v e d a a d a t a t a c t. S e e t a - F u e S1 v e v e a a - e d a t a c t c e c t e d f d f f e e t - e. I c e a t a t t e e d a t a t - e d t b t e d d e a e f v a u e b t e - a c u t e a u d a f e - e f e e d v a u e. A MD a u e d t a - e c f a t, t t e f a t (d g - e t e) f t t e t a c e t u. T e e f e, e e e d t c d e t e t e e e a a - (a - f t e a - e d d a t a t - e. Tu t u t u f a a t - c a t e e f a d e - d a a e a S e e t a - F u e S2A t t e 1-D d e d a a v a u e, S e e t a - F u e S2B.

T u d u d t e d f f e e c e a d a t a - b t e e t d a t a c t f t e a e f a e e t (d t e d a *k* b e) f t e d f f e e t t a - e c t e, t e d t a c e (. e u e d d f f e e c e) f e a c a f d a t a (e f e a c c t) a f t c - t e d a d t e d a d t a c e - t f d e *k* × *k*.

A t e a e d t a c e a e c e g e d a a t a u t f f v a u e (Pa a - d e I, t b e t t (e d) t a t a d a t a v a u e u_n c t 1 a d t v e a t a d a t a v a u e v_m c t 2 f t e a e d t a c e e t a t e u t f f. T e v e a e d d a t a a e a d t b e t a v e a - c u t e, a t e e d f t e t c t. T e v e a a t e t e d e f e d t b e t e a t f t e u - b e f v e a - d a t a a d t e u - b e f t t a u - b e f d a t a, .e. t e f a - e e t. W e - e c t e v e a v e a b t e e t e t c t, t e e c a b e t e e e e a t u a t :

1. Eve - d a t a c t 1 v e a t e a d - e d a t a c t 2. Tu, t e e c a b e a e t - e - de e d b t e e c t 1

a d ct 2. T e ve a cu te te ft ct, t e ve a ve a ate bt ee t et ct de ed a $k/k = 1$.
2. Ce ta u be f data (a) ct 1 d t e ve a t a-data ct 2, bt a data ct 2 ca be fu dt ve a t data ct 1. O te te, ce ta u be f data (a) ct 2 d t e ve a t a-data ct 2, bt a value ct 1 ca be fu dt ve a t data ct 2. T e ve-a cu te t e $k-a$ data, t e ve a ve a ate bt ca e ca be de ed edt be $(k-a)/k$.
3. Ce ta u be (a) f data ct 1 d t e ve a t a-data ct 2, a d ce ta u be (b) f data ct 2 d t e ve a t a-data ct 1. T e ve a cu te t e $k-a$, $k-b$ data, t e ve a ve a ate de ed a $(k-a)$, $(k-b)/k$.

Se e ta-Fu e S2D a a-a e ft e ve a a a-, e ec ced 1 eet a ve a cu te ce te ed at data d 1 f D P 198 M2/2CU, t adu eet t eut-ff va u e. A data f D P 198 M2/IXO t at ae t c ce d 1 a a ed t d 1, ave a d ca be ate ct eved a du edt c te t e ve a ate.

I te a a et te, e eedt date et eut ffu ed t e cu te a a-. A e a-t dt e t a ut ff va u e f cu te t a a-(et eft ct a de e dece f cu-te u be ve u ut ff va u e a Se e ta-Fu e S3. T e t a ut ff va u e u u a-c e att e t (Ta *et al.*, 2005). Se e ta-Fu e S3 t e t att e t-a ut ff t a-fed va u e bt de ed t e a ed data ct, b-ut at t ee d ffe et c ce f g t e MD f a e f cu te a a-.

Afe ce a tu du a data, ea ve att e te date eu t (, ve a ate) f eac e de eb-eac tu du a data t-e f eac a ft a ect e. T e fa eu t (δ, d t ate) ca be cau ated a $1-$, t bu ed t te.

Identification of important residues. T date e ct e a tu du a data ca e t ceab- e eedt ee ct a be c ut ff va u e, te edt e d. T def et et e d a ca a d at a a-, ef t a-(edt eave a ed t ate f eac tu du a data t-ef a e de e ada a ft a ect e te a ec dt . T e eu t te ave a ed t ate f a tu du a data t-e, cu et te ave a ed t ate te a ec dt a e t-<30% (.e. ea + ta da d dev at , Se e ta-Tabe S2), e a de f tu du a data t-e. M t u at ft e a a-(ed e de ce ted t ate <30% a d -fe e e de ct a tabe ca e tu du e (Se e ta-F S4 S6). T e ef e, ft ed t ate fa-tu du a data bet ee t t a ect e f d ffe et c dt ve 30%, e ca a-t at te tu du a data a e ca ed t ce-ab-bet ee t et t a ect e. Tu , t et e d a ct a 30% t det f-data t-et at ca ed t ceab- e c a d ffe et a ft a ect e f d ffe et c dt .

A te u et at e t c de te det fcat f t at e de te t c e MD at . I ve-c t at c ted ve a ate a dt e d t ate de ed te ec f a ft a ect eu ed. Tu , e c t d-t ate bet ee t d ffe et c dt , e eedt a-(e eve a ft a ect e. F a e, f eac -te ated *n* d ffe et t a ect e (d ffe et a d eed), t e e a e $N = n^2$ a ft a ect et be a a-(ed. If t e e a e M d t ate a tu du a data t-e be ca ed t ceab-, .e. e t at et e d, t e a f eu e c-at f M/N ft e a a e be ved t be t fcat-c a ed data t-e. If t e MD u at e e date t c, t e f eu e c-at u d be et e 100% 0%, .e. et e ca ed t t 100% ce ta t-H eve, t t e ca e. T e a ea abe f eu e c-e bu d, a ta a a-a f t c d ded f eve a a f-te. A eac -te a ated t 5 de e de t t a ect e, t e e e 25 a ft a ect et be c a ed. F a e, t e c a f M2 a d M2/IXO/2CU at , t e a a et te ead t at ta f 131 ca d date e de t at eat e t ceab-c a ed tu du a data at eat e a ft a ec-t e. A data ed d t, bt ft e e ca d date Se e ta-Fu e S7A. I ce a t at cu e ce f ca d date e de t 100% ce a ut a t e a a a-(ed. H eve, t e a a-t at a t-(85%) ft e ca d date e de e e be ved ve 90% ft e a a a-(ed. Se e ta-Fu e S7B a d C t ed t bt f t e t et c a-, a d t ec cu t e a e. T e ef e t tu d-, a e-de ec ded a a t at e de f at eat 90% ft e 25 a ft a ect e a e be ved t at eat e tu du a data ca ed t ceab-f t e e de.

U c t f Se (3) a d (4), e be ab et det f-a t f t at e de t at ave c a ed t ceab- c ected MD t a ect e f eac te . T e tabe d bc, eect t at ca d d e-b d te act a e t e det fed a de c bed Sect 2. Re de te act ed a e det fed f a tabe te act a a t at e de. T e te tet at a a-a e f edt det f tet a a at a-.

3.2 Algorithm validation

3.2.1 PKM2

Important residues responsible for Serine (SER) activation in PKM2. We e f ed a a-fa fu ated PKM2 t-e t det f t at e de (Se e ta-Tabe S3). A t eet e e a e 36 e de at eb d te a dd A f t e te au e (Se e ta-Tabe S4). T et t at e-de tab-ca ed ba ed te MD at . E e t t at a fe t e de a- e act va PKM2, ft e ca be det fed b- u d t tu d-(C a t *et al.*, 2012). Se e ta-Tabe S4 t att e e t at e de e e be ved ve-a e ca e te de cat-(C 1 a d C 2) a dcated b- te d t ate (≥70%≥ 70%). I t te t at u a ac a e-t vt-(80.00%) bt a e fct-(30.77%) det f t-at e de t e PKM2 t e.

D t bt ft e t at e de eac e t ted Se e ta-Tabe S5. Se e ta-Fu e S8A a d B t at about f ft e t at e de a e cated te cata-c d (A d). T dcate t at e cata-c d ca ed tu b d t te a te cact va .

Residue interaction networks. Fu e 2 t e e de te-act ct c tu ed f t e t at e de det fed b- DIRN. T e t at e de a e ce a-cu te ed t ef (A a d C d) a d t u (B d) e a ated b- t e da e. N ct c ect a fu d bet ee u bt ate OXL a da-de t ef u PKM2/OXL a d PKM2/OXL/FBP, bt a c ect t u Mct 360 a fu d PKM2/OXL/SER a d PKM2/OXL/FBP/SER. T dcate t at f ca t be t a fe ed t OXL PKM2/OXL t t ut FBP e et, e a te c eu at SER ca ead t c ect f e ef u t OXL t u te act a t e t at e de. T e e a ec tet t t e e t e tt at e PKM2 ca be bted b- OXL t e e ce FBP (D u a *et al.*, 2005) eu c effect ca be ed ced b- SER (C a t *et al.*, 2012).



Fig. 2. Residue interaction networks formed by important residues in PKM2 systems simulated. OXL is the substrate for PKM2, SER and FBP act as activators. All three are shown as yellow spheres. Red-colored spheres are placed at the CA atoms of important residues. Sphere size represents the disjoint rate of the represented residue. (**A**) PKM2/OXL. (**B**) PKM2/OXL/SER. (**C**) PKM2/OXL/FBP. (**D**) PKM2/OXL/FBP/SER

e ta Tab e S6 t t e 33 te ac a ted t e te au e (C a et al., 2012; D et al., 2005; M a et al., 2013). A t e et e e a e 19 te ac , e u ac de t fed 17 ft e et be tat . M t a e de t fed a d e b d . T t a d e -b d te ac a e t e f ce be f t e PKM2 ac vat a t e b d te a d A d . C a t t e de t fcat f tat e d e , u d e e t ve de t f te ac a t e tat e d e , t a tu t ve a e f ~89%. T e d' ec f ct a a bt bat e a ~57%. T t a addt a ef e t f u a - t de t f tat e d e ece a .

t t t a t e e d e , u c a H 464, T 482, T 515 a d A 516, c a ea d a e de t fed b t e t a d c ta (e f Supp e ta Mate a).

3.2.2 GPCR M2

Important residues responsible for GPCR M2 activation. We e - f d a t bet ee t e ac ve a d eac ft e ac ve tate e b et vet a e t e tat e d e e be f t ac vat . Supp e ta Tab e S8 t t e ve e d e f t ee f abut 100 tat e d e , be evedt bet e t tat f t e M2 ac vat . A t e e e d e , f t e u c a T -80, A 103, T -104, A 120, T -206, T -400, T -403 a d A 404, a e ted f eu et e t f t e a e ve cu ca f M2 ac vat t e e ce f a t (Ha a et al., 2012; Ku e et al., 2013; M a et al., 2013, 2014). T e e a e t ta 20 e d e a ed t ee e t a ted Supp e ta Tab e S9. A a t e e e d e , 17 e d e e e de t fed t be e et a bt t e te au e a d b u d . MD a t a t ft e c a e a e C 1 C 2 dec a a e , t d t a e ve 90%. Supp e ta Tab e S9 t a t e e t vt ft e d ca eac 100%, bt t ec f ct a 67%. T e ve a d t bt f tat



Fig. 3. Residue interaction networks formed by identified residues in GPCR M2 systems simulated. IXO and 2CU are activators for M2 which are shown as yellow spheres. Red-colored spheres represent the CA atoms of important residues. Sphere size represents the disjoint rate of the represented residue. (**A**) M2. (**B**) M2/IXO. (**C**) M2/2CU. (**D**) M2/IXO/2CU

e d e eac e t ted Supp e ta Tab e S10 a d F u e S9.

Residue interaction networks. T e e a e u d ed f t e ac a a de t fed tat e d e . He e t e 22 t e ac- t a a ed t e te au e a e Supp e ta Tab e S11 (Ku e et al., 2013; M a et al., 2014). Ou t ft e 22 t e ac- t , 20 a e te ac f ac vat M2 ecet a d t ft e a e d e -b d te ac bt ee a d a d u - u d e d e . T e e t vt a d ec f ct f u ac t e M2 ecet a a a e 100.00 a d 50.00%, e ect ve . T d cate t a t te ac v v t e tat e d e ca be de t fed b DIRN t acu ac . T e ec f ct e e c te t a a e a ed.

T e e d e te ac a a t e tat e d e ca be d v ded t ef a d t e (F . 3). T e e c ect bt ee ef a d t e t e ft e ac vat ed M2 e c ect e e t e ft e ac vat ed tate , u d M2/IXO, M2.2CU a d M2/IXO/2CU. I M2/IXO, t e e e b d e (P e396 T -206) t e t e , t ve cu ca f a . T c tet t t e tt a t e Y206F at ecet ca t be ac vat ed b ac c e a d a ve ea a eu t ea t t IXO (Ku e et al., 2013). I M2/2CU, t e e a e t b d e fu d (P e396 T -440 a d P e396 O -439). I M2/IXO/2CU t e e a e a t b d e (P e396 T -440 a d P e396 T -206). O a a tu t a M2/IXO/2CU a d M2/2CU ave ve a c ect bt ee t e ef t t e . I u f a ac vat ed e , t cea t a P e396 ve cu ca f t e ef a d t e ft e e d e te ac (L a d C e , 2018).

3.2.3 GPCR κOR

Important residues responsible for GPCR OR signal transduction. T e ve e d e ft ee f abut 100 tat e - d e a e ted Supp e ta Tab e S13. P ev u e t u ded 11 e d e t u t t be tat t e ac vat f OR (Supp e ta Tab e S14) (C e et al., 2016). Ou t ft e 11 e d e a a ed, 9 e e fu d t be tat , a d 7 e d e e e de t fed t be e et a bt te au e a d t u d (C e et al., 2016). Supp e ta Tab e S14 t a u d ac eve bt e t vt (77.78%) a d ec f ct



Fig. 4. Residue interaction networks formed by important residues in GPCR OR systems simulated. (**A**) OR/5′-GNTI. (**B**) OR/6′-GNTI. (**C**) OR. 5′-GNTI acts as the inhibitor and 6′-GNTI acts as the activator, both shown as yellow spheres. Red-colored spheres represent CA atoms of important residues. Sphere size represents the disjoint rate of the represented residue

(100.00%) f t ecgt . W t t ut a e A 138, T 139, T 287, I e294 a d Gu 297 t at a tat e bt 6′-GNTI a d OR/5′-GNTI te , at u te f ac- t ve et e ate act ve,t dcate t ee e de e f fcat t dffe et a t a f e ecgt ta- tu (C e *et al.*, 2016). T ed t bt f de t fed e de eac e et t ted Sae e ta -Tab e S15 a d Sae e ta -Fu e S10.

Residue interaction networks. A te act a a ed te- eau e a e Sae e ta -Tab e S16 (C e *et al.*, 2016). Ot ft e 18 te act , 15 e e fu dt be tat f act- vat OR ecgt a dt e e a e k f d e -b d, at- b d ead d bc te act . T e e t vt -a d ecf ct fu a ac te OR ecgt a a - a eb t ve , at 93.33 a d 66.67%, e ect ve - T e de te act a e Fu e 4.

3.3 Comparison with other methods

I t tud , e ved t e te d b e- eed t fc a - tat e de te teu ft e de te act . Sae e ta -Fu e S11 t at e e a e a - te e de (bue ee) a ded e v ved te d- b -IN a d DCN. T e t t e a e ted Sae e ta -Tab e S18. T e ece ft ee e de te d- a t v ab de e de t f a a at a - .

Ot t at e - e-eed tat e de t te MD- ba ed a ac ce a - ve te e t vt - ft e d. Sae e ta -Tab e S19 t at DIRN at e et e t v- t - de t f - bt tat e de ad tat te act a t et ee d c a ed.

We a c a edt e a te c at a - f t et eeteted te (Sae e ta -Tab e S20 S22). He e ave a - tedt e tat e de de t fed e v u e et t be tat te at a - . I ce at IN a d DCN de t f- fe e uc e de te at a - . I deed, e ft e e- e de ca be de t fed bt PKM2 a d OR.

4 Conclusion

We deve ed a e a ac ,te d DIRN,t de t f - tat e de e bef a te - b - t tec f a a ca e d uced b - a dbd . I t a ac , MD a- t ee f tc d ted f ata d te dffe et c dt e bu dt dffe et a d. Nt t a d eated data e e t ed f tetac f a ca e. T f- ed b a a t bt ee dffe et c dt t cee f tat e de t et ata e fu dt ca e fcat - acc d t t ted tu u a data. O ce tat e de ae det- fed,t e - a ut (eda det c tu t a e de te act t- u de ta d e - a a t a f a te - T e e a ac a va dated b - c a t e et a f d a da t t d uc ate e de te act t- a dd - a ca c eat t d. Ou a a - t at DIRNte d t - eda e e t v- t - bt e ec fct - t ate e de te act t a d d - a ca c eat t d. Tu DIRN e bt c ee f tat e de / te act t e tue t ve eut ,tu t a e at fact - f d tue e at ve e de / te act . Afe a ca et a a - , e fu d e ea f t eve - tue e at ve ate PKM2t be t efa e t ve e de det fed b -NMR caa cu c- tat . If e e eat t e a a - t utt e caa cu c- tat , ve a te e ec fct - ca be ved a Sae e ta -Tab e S23. S ec fca - t e e ec fct - c ea ed f 30.77t 50.00% f PKM2, t ut c ca e te e t vt - at f a t ee - te . I e - t eu e f caa cu c tat eu e dffe et t f a a de e at et- a a et at u d eav - e e . I a a ua be t at DIRN' te de c t e ed t a a e t f e de t be tat a - ead t e e t vt - F ca e,t e e a e 281 e de GPCR OR, abut 140 f c a e ed t ed t be tat e de b -DIRN (Sae e ta -Tab e S15). We c tue t (u a act t vet e f a ce. Nevet ee , teu et d ca e ve a au et fte t fac tat e e ta tude b v d u et ta t ee tude f te a te - .

Funding

T a u ted b - Ce te f HPC at Sa a Ja T U ve t - t e Na a Ke - Re ea c a d Deve et P a- f C a (2018YFC0310803 a d 2017YFE0103300), t e Na a Nau a Sce ce Fu dat f C a (31770771 a d 31620103901), Med ca E ee C B d f Sa a Ja T U ve t - (YG2017MS08) a d Na a I tute f Heat /NIGMS (GM093040 a d GM079383).

Conflict of Interest: e dec a ed.

References

Abd -R d a,A. (2014) Mec a t c t t a te c tu u et t e at e M1 ca cacd - c e ecgt . *J. Biol. Chem.*, **289**, 33701 33711.

A bet ,R. *et al.* (2000) E a d at ac t ea e f c . *Nature*, **406**, 378 382.

A a,G. *et al.* (2004) Na a a - f te tu u e det t- t a e de . *J. Mol. Biol.*, **344**, 1135 1146.

A e v,Y. *et al.* (2008) C t t ca a a de f b ca c- . *Bioinformatics*, **24**, 282 284.

C a t ,B. *et al.* (2012) Se e a a a da da te cact va f u va a e M2. *Nature*, **491**, 458 462.

C e ,H.F. (2008) Mec a f cu ed f d a d b d te RNA PAZ c . *J. Chem. Theory. Comput.*, **4**, 1360 1368.

C e ,H.F. a d u ,R. (2007) B d d ced f d 53-MDM2 c . *J. Am. Chem. Soc.*, **129**, 2930 2937.

C e ,J. *et al.* (2016) M eu a tc e ft e a d ecgt t- e ed b -6′-GNTI a d 5′-GNTI. *Sci. Rep.*, **6**, 18913.

Ce ,P. (2008) C eat ve e e et : t -ba ed ed t f act ve ce t e te a d ceu a a d ca t . *Trends Biochem. Sci.*, **33**, 569 576.

De S ,A. *et al.* (2007) M di a a c teu e f te tu du e a d a - te c c cat : te t a cat f a te a d eu at a e . *Genome Biol.*, **8**, R92.

D Pa a,L. *et al.* (2013) P te c tact t : a e a a d c e t . *Chem. Rev.*, **113**, 1598 1613.

D a ,N.V. *et al.* (2002) T ca date at f te f d . *Proc. Natl. Acad. Sci. USA*, **99**, 8637 8641.

D ,J.D. *et al.* (2005) Stu du a ba f u u a e M2 a te c eu at a d cat a . *Biochemistry*, **44**, 9417 9429.

Ga c a-Ga c a,C. *et al.* (2003) E ect tat c te act a a t de RNA c . *J. Mol. Biol.*, **331**, 75 88.

Gu ,X. *et al.* (2017) C f at d a- c f te t ca - d de ed te c-M b t te ff99IDP f ce ed. *RSC Adv.*, **7**, 29713 29721.

Ha a,K. *et al.* (2012) Stu du e ft eu M2 ca ca act c e e- ce t bu dt a ata t . *Nature*, **482**, 547 551.

H ta ,A. *et al.* (2015) M eu a d a- c at : adva ce a da - cat . *Adv. Appl. Bioinform. Chem.*, **8**, 37 47.

J ,Z. *et al.* (2016) S - e tc d cat d ced ec c ec t bet ee t ea d TRIM24 va u du at c eat at a a - .

Ku e,A.C. *et al.* (2013) Act vat a da te c d at fa ca c act c e ec t . *Nature*, **504**, 101 106.

L ,Q. a d C e ,H.-F. (2018) S - e tc eu at c a f e a d LY2119620 f ca c act c e M2 ec t . *RSC Adv.*, **8**, 13067 13074.

Lu ,H. *et al.* (2017) P t vec e at ve eu at f du be d te f u a act c e te a e. *Chem. Biol. Drug Des.*, **89**, 694 704.

Lu ,R. a d Hu ,J. (2011) C tat a ed t fe e-b d e d e b t e d e te act t . *PLoS One*, **6**, e25560.

McG bb ,R.T. *et al.* (2015) MDT a : a de e ba a - f t ea a - f eu a d a- t a ct e . *Biophys. J.*, **109**, 1528 1532.

Ma ,Y. *et al.* (2013) Act vat a d a- c t ft e M2 ca c ec t . *Proc. Natl. Acad. Sci. USA*, **110**, 10982 10987.

Ma ,Y. *et al.* (2014) Ma f a te c du abe te act vat -a cated c f ft e M2 ca c ec t . *Chem. Biol. Drug Des.*, **83**, 237 246.

M a ,H.P. *et al.* (2013) M2 u va e a e v de a ec a f ut et e a d eu at f ce fe at . *Proc. Natl. Acad. Sci. USA*, **110**, 5881 5886.

Ra ,M.U. *et al.* (2016) A te c ec a f c - d be (a- (e e bt f HCV NS5B RdR va a- c c eat at a a - . *Mol. Biosyst.*, **12**, 3280 3293.

Sat ,A. *et al.* (2009) D a- ca at tRNA: te c e. *Proc. Natl. Acad. Sci. USA*, **106**, 6620 6625.

Su da a a a ,V. *et al.* (2010) At c te act at t ec e f te d a dte at ve f d . *PLoS One*, **5**, e9391.

Si e ,G.M. *et al.* (2003) Ev ut a - c e ved at f e de ed date a te cc cat te . *Nat. Struct. Biol.*, **10**, 59 69.

Ta ,P.N. *et al.* (2005) *Introduction to Data Mining*. 1 ted . Add -We e - L B b C ., I c, B t .

Wa ,W. *et al.* (2016) D a- c c eat at f a te c tc f P eQ1 R b tc . *Sci. Rep.*, **6**, 31005.

Wa ,W. *et al.* (2014) Ne f ce ed de t ca - d ded te . *Chem. Biol. Drug Des.*, **84**, 253 269.

Ya ,J. *et al.* (2016) S - e tc a te c ec a ff u t e-1, 6-b - ea d e f u va e a e M2 v a d a- c u du at at a a - . *J. Chem. Inf. Model.*, **56**, 1184 1192.

Ye,W. *et al.* (2017) A te c t bt a a - t a c t fact ERG: d a- c at a d at e e ta eva at . *J. Chem. Inf. Model.*, **57**, 1153 1165.

Z a ,J.M. *et al.* (2016) S - e tc d cat d ced ec c ec t bet ee t ea d TRIM24 va u du at c eat at a a - . *Sci. Rep.*, **6**, 24587.

Z a ,J.M. *et al.* (2017) A te g at a - t a d f at e e b - tc t d a- c c eat at . *Mol. Biosyst.*, **13**, 156 164.